Impavido, Drug To Treat Parasitic Disease Leishmaniasis, Backed By FDA Panel
Category: WELLNESS
Impavido was granted priority review by the FDA, a status that cuts the review time to six months from the standard 10. Priority
By Reuters, Reuters, 2013-10-18